Skye Bioscience, Inc. (SKYE)
0.9901
-0.05
(-4.80%)
USD |
NASDAQ |
Nov 06, 10:33
Skye Bioscience Net Income (Quarterly) : -10.79M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.79M |
| March 31, 2026 | -12.51M |
| December 31, 2025 | -14.44M |
| September 30, 2025 | -12.75M |
| June 30, 2025 | -17.62M |
| March 31, 2025 | -11.10M |
| December 31, 2024 | -9.746M |
| September 30, 2024 | -3.898M |
| June 30, 2024 | -7.903M |
| March 31, 2024 | -5.020M |
| December 31, 2023 | -4.420M |
| September 30, 2023 | -24.95M |
| June 30, 2023 | -3.112M |
| March 31, 2023 | -5.168M |
| December 31, 2022 | -9.892M |
| September 30, 2022 | -3.127M |
| June 30, 2022 | -3.419M |
| March 31, 2022 | -3.043M |
| December 31, 2021 | -2.513M |
| September 30, 2021 | -1.825M |
| June 30, 2021 | -2.024M |
| March 31, 2021 | -2.160M |
| December 31, 2020 | -1.502M |
| September 30, 2020 | -1.297M |
| June 30, 2020 | -1.420M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.342M |
| December 31, 2019 | 4.852M |
| September 30, 2019 | -4.931M |
| June 30, 2019 | 15.91M |
| March 31, 2019 | -14.77M |
| December 31, 2018 | -6.222M |
| September 30, 2018 | -2.096M |
| June 30, 2018 | -2.662M |
| March 31, 2018 | -8.214M |
| December 31, 2017 | -0.6282M |
| September 30, 2017 | -0.4801M |
| June 30, 2017 | -0.7028M |
| March 31, 2017 | -1.283M |
| December 31, 2016 | -1.120M |
| September 30, 2016 | -0.9453M |
| June 30, 2016 | 0.5731M |
| March 31, 2016 | -1.685M |
| December 31, 2015 | -0.6912M |
| September 30, 2015 | -1.183M |
| June 30, 2015 | -2.057M |
| March 31, 2015 | -0.9102M |
| December 31, 2014 | -1.703M |
| September 30, 2014 | -0.8585M |
| April 30, 2014 | -0.0135M |
| January 31, 2014 | 0.0036M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 10.79M |
| EPS Diluted (Quarterly) | -2.174 |
| Enterprise Value | -5.317M |
| Earnings Yield | -1.03K% |
| Normalized Earnings Yield | -981.92 |